Valeant VRX Bill Ackman Pershing Square

Bill Ackman On Valeant Conference Call [SLIDES]

Bill Ackman’s slides from his investor conference call on Valeant.

Valeant Pharmaceuticals International (VRX)

  • Multinational specialty pharmaceutical company
  • Leader in dermatology, ophthalmology, branded generics, and gastroenterology
  • Significant presence in both developed and emerging markets
  • Market cap of ~$40bn and TEV of ~$68bn
  • Approximately 40 manufacturing plants worldwide
  • ~18,000 employees(1)

Valeant: Context on the Company

  • In February 2008, when Mike Pearson was named CEO, Valeant was a small, struggling company
  • Pearson changed Valeant’s strategy to incorporate:
    • A durable, diverse portfolio of products in specialties where doctors are decision makers, with limited government reimbursement
    • Decentralized, efficient, nimble organizational structure
    • Return-driven capital allocation framework (M&A, high ROI R&D, buybacks)
    • Rapid growth
    • Diverse portfolio of products
    • Numerous drivers of value creation
    • Numerous acquisitions
      • Purchased distressed assets, inherited multiple Corporate Integrity Agreements
    • Utilized leverage
  • Valeant’s business and strategy are complicated to understand; GAAP accounting is an inadequate measure of an acquisitive company
    • Investor base has historically consisted of sophisticated, long-term investors (Ruane Cunniff & Goldfarb, T Rowe Price, ValueAct, Lone Pine, Brave Warrior, Brahman Capital, etc.)
  • Valeant’s complexity necessitates:
    • Strong, high-integrity management
    • High level of transparency
  • Anything less than complete transparency leaves Valeant susceptible to attack
  • Valeant’s implicit compact with shareholders: in exchange for high returns, investors accept complexity so long as there is transparency
  • Valeant has underinvested in public relations, government relations, and investor relations. This has been a very costly mistake

Valeant: Recent Events

A. Price Increaces

  • Volume is primary growth driver for ~90% of Valeant’s business
  • Media reports are focused on gross prices; net realized prices to manufacturer are much lower
  • Drugs improve health outcomes and can reduce overall cost of healthcare; returns on investment critical to drug innovation

B. VRX’s Perceived “Strategy Shift”

  • VRX’s strategy is multi-faceted, focused on creating shareholder value, adapts with opportunities:
    • M&A: No more “price increase” deals (only 4 of ~150 historical acquisitions)
    • R&D: Increasing modestly to pursue attractive late-stage development opportunities

Valeant VRX Bill Ackman Pershing Square

See full slides below.


Saved Articles

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

Congrats! Are you a smart person?

We have an exclusive targeted & limited time offer for being a sophisticated and loyal reader.

ValueWalkPremium is a website and newsletter on the latest industry news much of which is not in the public domain and obtained via our sources.

We also have 10 years of resources on how to use this information to better your investment process.

Sign up for  today and get our exclusive content for 40% off. This is our second biggest discount ever!!

Use coupon code VIP20 or click on the button below

Limited time offer only ENDS 4/30/2020 or after the next 40 subscribers take advantage whichever comes first – please do not share this discount with others